Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.

EPRX

Eupraxia Pharmaceuticals (EPRX)

Eupraxia Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:EPRX
DateTimeSourceHeadlineSymbolCompany
07/03/20244:00PMPR Newswire (US)Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Exploring the Rapid Rise of Osteoarthritis" on July 9, 2024NASDAQ:EPRXEupraxia Pharmaceuticals Inc
07/03/20244:00PMPR Newswire (Canada)Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Exploring the Rapid Rise of Osteoarthritis" on July 9, 2024NASDAQ:EPRXEupraxia Pharmaceuticals Inc
06/06/20244:01PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:EPRXEupraxia Pharmaceuticals Inc
06/06/20244:00PMPR Newswire (US)Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of ShareholdersNASDAQ:EPRXEupraxia Pharmaceuticals Inc
06/06/20244:00PMPR Newswire (Canada)Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of ShareholdersNASDAQ:EPRXEupraxia Pharmaceuticals Inc
06/05/20246:01AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:EPRXEupraxia Pharmaceuticals Inc
06/05/20246:00AMPR Newswire (US)Eupraxia Pharmaceuticals to Present Data from the Phase 2 SPRINGBOARD Study in Osteoarthritis of the Knee at EULAR European Congress of Rheumatology 2024NASDAQ:EPRXEupraxia Pharmaceuticals Inc
06/05/20246:00AMPR Newswire (Canada)Eupraxia Pharmaceuticals to Present Data from the Phase 2 SPRINGBOARD Study in Osteoarthritis of the Knee at EULAR European Congress of Rheumatology 2024NASDAQ:EPRXEupraxia Pharmaceuticals Inc
05/23/20244:04PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:EPRXEupraxia Pharmaceuticals Inc
05/23/20244:00PMPR Newswire (US)Eupraxia Pharmaceuticals Announces Expansion of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic EsophagitisNASDAQ:EPRXEupraxia Pharmaceuticals Inc
05/23/20244:00PMPR Newswire (Canada)Eupraxia Pharmaceuticals Announces Expansion of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic EsophagitisNASDAQ:EPRXEupraxia Pharmaceuticals Inc
05/22/20246:04AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:EPRXEupraxia Pharmaceuticals Inc
05/22/20246:00AMPR Newswire (Canada)Eupraxia Pharmaceuticals to Host Virtual KOL Event on EP-104GI Clinical Development Program for Eosinophilic Esophagitis ("EoE") on May 29, 2024NASDAQ:EPRXEupraxia Pharmaceuticals Inc
05/22/20246:00AMPR Newswire (US)Eupraxia Pharmaceuticals to Host Virtual KOL Event on EP-104GI Clinical Development Program for Eosinophilic Esophagitis ("EoE") on May 29, 2024NASDAQ:EPRXEupraxia Pharmaceuticals Inc
05/21/20244:05PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:EPRXEupraxia Pharmaceuticals Inc
05/21/20244:00PMPR Newswire (Canada)Eupraxia Pharmaceuticals Announces New Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic EsophagitisNASDAQ:EPRXEupraxia Pharmaceuticals Inc
05/21/20244:00PMPR Newswire (US)Eupraxia Pharmaceuticals Announces New Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic EsophagitisNASDAQ:EPRXEupraxia Pharmaceuticals Inc
05/15/202411:00AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:EPRXEupraxia Pharmaceuticals Inc
05/14/20246:04AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:EPRXEupraxia Pharmaceuticals Inc
05/14/20246:00AMPR Newswire (US)Eupraxia Pharmaceuticals to Present Initial Results from Ongoing Phase 1b Study of EP-104GI for the Treatment of Eosinophilic Esophagitis at Upcoming Digestive Disease Week Annual Meeting 2024NASDAQ:EPRXEupraxia Pharmaceuticals Inc
05/14/20246:00AMPR Newswire (Canada)Eupraxia Pharmaceuticals to Present Initial Results from Ongoing Phase 1b Study of EP-104GI for the Treatment of Eosinophilic Esophagitis at Upcoming Digestive Disease Week Annual Meeting 2024NASDAQ:EPRXEupraxia Pharmaceuticals Inc
05/08/20244:05PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:EPRXEupraxia Pharmaceuticals Inc
05/08/20244:03PMPR Newswire (Canada)Eupraxia Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:EPRXEupraxia Pharmaceuticals Inc
05/08/20244:03PMPR Newswire (US)Eupraxia Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:EPRXEupraxia Pharmaceuticals Inc
05/02/20246:00AMPR Newswire (US)Eupraxia Pharmaceuticals Announces Gastrointestinal Clinical Advisory BoardNASDAQ:EPRXEupraxia Pharmaceuticals Inc
05/02/20246:00AMPR Newswire (Canada)Eupraxia Pharmaceuticals Announces Gastrointestinal Clinical Advisory BoardNASDAQ:EPRXEupraxia Pharmaceuticals Inc
04/11/20246:00AMPR Newswire (US)Eupraxia Pharmaceuticals Announces Upcoming Presentations at the Osteoarthritis Research Society International World Congress 2024NASDAQ:EPRXEupraxia Pharmaceuticals Inc
04/11/20246:00AMPR Newswire (Canada)Eupraxia Pharmaceuticals Announces Upcoming Presentations at the Osteoarthritis Research Society International World Congress 2024NASDAQ:EPRXEupraxia Pharmaceuticals Inc
04/08/20246:00AMPR Newswire (US)Eupraxia Pharmaceuticals To Present at Bloom Burton & Co. Healthcare Investor ConferenceNASDAQ:EPRXEupraxia Pharmaceuticals Inc
04/08/20246:00AMPR Newswire (Canada)Eupraxia Pharmaceuticals To Present at Bloom Burton & Co. Healthcare Investor ConferenceNASDAQ:EPRXEupraxia Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:EPRX

Your Recent History

Delayed Upgrade Clock